Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 12, 2025
Product Development
What Arvinas’ data say about target selection
Focusing on the crowded SERD space left little room for differentiation
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New modality showdowns
Genetic therapies compete in the same indications, as degraders come of age
BioCentury | Dec 7, 2024
Finance
Revolution, Janux prep for next steps with follow-on cash
In BioCentury’s Public Equity Report: Oncology companies tap public markets for more than $1.2B, while Olema draws $250M PIPE for Novartis combo trial
BioCentury | Jun 13, 2023
Deals
June 12 Quick Takes: AZ’s first-in-class AKT inhibitor under review
Plus: Simcere grows Massachusetts presence, and updates from Eisai, Bliss, Eccogene, Phathom, Ironwood and more
BioCentury | Jan 28, 2023
Regulation
Jan. 27 Quick Takes: FDA approves first oral SERD
Plus: FDA approves Jaypirca, Lilly’s non-covalent Btk inhibitor and updates from Novartis, Legend, Goldfinch Bio and Relive
BioCentury | Dec 10, 2022
Product Development
Lessons emerging from the evolving SERD landscape
AstraZeneca’s camizestrant data cap progress in oral SERDs, a class that is figuring out how to demonstrate benefit against changing competition
BioCentury | Mar 5, 2022
Discovery & Translation
Three ways to selectively kill cancer cells; plus Aevis and more
BioCentury’s roundup of translational news
BioCentury | Feb 24, 2022
Finance
Fresh off Amgen deal, Plexium raises $102M for degrader platform
BVF Partners, TCG Crossover co-lead funding to advance Plexium’s cell- and DEL-based degrader discovery tech
BioCentury | Feb 2, 2022
Emerging Company Profile
Ambagon: creating molecular glues for disordered proteins
Nextech Invest leads $85M series A to make the difficult-to-drug protein class amenable to small molecules
BioCentury | Oct 21, 2021
Product Development
Menarini poised for upside from Radius deal as breast cancer results point to submission
Elacestrant meets Phase III endpoints, rewarding Menarini’s appetite for risk
Items per page:
1 - 10 of 46